You're getting 1/3 or shares free as an options, as soon as CR saga settles the SP appreciation will start as institutional entitlement is non-renounceable offer so they are not selling. The price target is $6.50 if successful after Phase 3 readouts for COAST (Combination OPT-302 with Aflibercept Study), and ShORe (Study of OPT-302 in combination with Ranibizumab),
The safety and superior efficacy of Sozinibercept is proven, than Sky is the limit after next readout
Ann: Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens, page-5
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $477.0M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 38.0¢ | $40.03K | 103.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 164443 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 168976 | 13 |
View Market Depth
| Last trade - 14.19pm 23/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |